Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2012
03/08/2012WO2012029067A1 Crystalline forms of maraviroc phosphate and process for maraviroc amorphous form
03/08/2012WO2012028966A2 Combination dosage compositions comprising a cholesterol-lowering agent, a renin-angiotensin system inhibitor, an antioxidant agent and an antiplatelet agent for treatment and prevention of cardiovascular disease
03/08/2012WO2012028935A1 Dietary supplement
03/08/2012WO2012028934A1 Pharmaceutical composition comprising metformin and pioglitazone
03/08/2012WO2012028922A2 Controlled release pharmaceutical compositions of milnacipran
03/08/2012WO2012028874A1 Cytotoxic luminescent metal complexes
03/08/2012WO2012028861A1 Pure erlotinib
03/08/2012WO2012028834A1 Use of bupropion in treating sexual dysfunction
03/08/2012WO2012028757A1 Fluorinated thiazoles for use in treating cancer
03/08/2012WO2012028732A1 Novel uses of v-atpase inhibitors
03/08/2012WO2012028698A1 Mesalazine tablet having improved dissolution
03/08/2012WO2012028688A1 Rheumatoid arthritis treatment using polyunsaturated long chain ketones
03/08/2012WO2012028663A1 Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
03/08/2012WO2012028662A1 Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
03/08/2012WO2012028647A1 Bicyclic aza heterocycles, and use thereof
03/08/2012WO2012028644A1 Substituted n-phenethyltriazoloneacetamides and use thereof
03/08/2012WO2012028635A1 Deuterated analogs of pridopidine useful as dopaminergic stabilizers
03/08/2012WO2012028629A1 2 - (benzyloxy) benzamides as lrrk2 kinase inhibitors
03/08/2012WO2012028614A1 5-ht2b receptor antagonists
03/08/2012WO2012028585A1 Adenosine a1 agonists for the treatment of glaucoma and ocular hypertension
03/08/2012WO2012028563A1 Bace inhibitors for use in the treatment of diabetes
03/08/2012WO2012028556A1 Macrocyclic lactones and their use and their combinations with other active substances
03/08/2012WO2012028543A1 Composition comprising a combination of dha and epa for administration prior to commencement of chemotherapy
03/08/2012WO2012028340A1 Preventive ointment for diabetic foot
03/08/2012WO2012028335A2 Kinases as targets for anti-diabetic therapy
03/08/2012WO2012028332A1 Pharmaceutically active compounds as axl inhibitors
03/08/2012WO2012028331A1 Substituted tetrahydropyrrolopyrazine derivatives
03/08/2012WO2012028311A1 Compositions comprising a taxane for coating medical devices
03/08/2012WO2012028310A2 Pharmaceutical compositions comprising a taxane
03/08/2012WO2012028300A1 Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as kcnq2/3 modulators
03/08/2012WO2012028243A1 Pyrazolopyridinone derivatives as lpa receptor antagonists
03/08/2012WO2012028233A1 Imidazo[4,5-c]quinolines as dna-pk inhibitors
03/08/2012WO2012028106A1 Deuterium-enriched heterocyclic compounds as kinase inhibitors
03/08/2012WO2012028100A1 Novel compounds
03/08/2012WO2012028056A1 A clinical preparation of scutellarin and the preparation method thereof
03/08/2012WO2012027972A1 TENOFOVIR DISOPROXIL FUMARATE α-CRYSTAL FORM, PREPARATION METHOD AND APPLICATION THEREOF
03/08/2012WO2012027968A1 Panaxatriol saponins enteric pellet, capsule comprising same and method for preparing same
03/08/2012WO2012027965A1 Novel compounds
03/08/2012WO2012027960A1 Quinazoline derivatives substituted by aniline, preparation method and use thereof
03/08/2012WO2012027957A1 Bufalin derivatives, pharmaceutical compositions and use thereof
03/08/2012WO2012027825A1 Method of treating dopamine-related neuropsychiatric disorders
03/08/2012WO2012027811A2 Anesthetic association, anesthetic composition, and anesthetic medicament for veterinary use
03/08/2012WO2012027797A1 Anti-inflammatory compostion
03/08/2012WO2012027794A2 Method of treatment and agents useful for same
03/08/2012WO2012017128A3 Composition based on rosemary extract and vitamin e and uses thereof
03/08/2012WO2012012300A3 Treatment of the adverse side-effects associated with administration of an anti-hyaluronan agent
03/08/2012WO2012007877A3 N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
03/08/2012WO2012007869A3 N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
03/08/2012WO2012007868A3 N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
03/08/2012WO2012003912A8 Bipyridyl derivatives useful for the treatment of kinase - induced diseases
03/08/2012WO2012002986A3 Decellularized and delipidized extracellular matrix and methods of use
03/08/2012WO2012002379A9 Fish parasite extermination agent and extermination method
03/08/2012WO2011161245A3 Polymorphs of febuxostat
03/08/2012WO2011158248A3 Process for preparation of posaconazole and crystalline polymorphic form v of posaconazole
03/08/2012WO2011152652A3 Aceclofenac slow-release preparation providing an optimum pharmacological clinical effect when administered once a day
03/08/2012WO2011151618A3 Compounds for the treatment of clostridium difficile associated disease (cdad)
03/08/2012WO2011150393A9 Methods for improving maternal and fetal health
03/08/2012WO2011146892A9 Methods and compositions for treating disorders associated with impaired insulin production or secretion
03/08/2012WO2011146804A3 Gm3 ganglioside replacement therapy
03/08/2012WO2011146675A3 Treatment of lim homeobox 2 (lhx2) related diseases by inhibition of natural antisense transcript to lhx2
03/08/2012WO2011146032A3 Effervescent formulations
03/08/2012WO2011143160A9 Metabolic inhibitor against tumors having an idh mutation
03/08/2012WO2011142731A3 Formulations comprising a third generation cephalosporin and clavulanic acid
03/08/2012WO2011142621A3 Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbesartan
03/08/2012WO2011140334A3 Compounds, methods of making or identifying compounds, and uses thereof
03/08/2012WO2011140315A3 Method of reducing proteins misfolding and/or aggregation
03/08/2012WO2011139881A3 Compositions containing purine and pyrimidine nucleosides, peptides, and manganese and their uses
03/08/2012WO2011139765A3 Compounds that modulate intracellular calcium
03/08/2012WO2011139684A3 Nicotine-containing pharmaceutical compositions
03/08/2012WO2011138427A3 Pyridazinones as gpr119 agonists
03/08/2012WO2011133875A3 Metalloenzyme inhibitor compounds
03/08/2012WO2011133819A3 Methods of enhancing antibody-dependent cellular cytotoxicity
03/08/2012WO2011133727A3 Anti-viral compounds
03/08/2012WO2011133696A3 Methods of suppressing atherosclerosis
03/08/2012WO2011133475A3 Compositions and method for the treatment of multiple myeloma
03/08/2012WO2011132967A3 Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same
03/08/2012WO2011132161A3 Sulodexide for use in the treatment of pathologies wherein metalloproteinases are involved
03/08/2012WO2011130740A3 Pyridylthiazole-based ureas as inhibitors of rho associated protein kinase (rock) and methods of use
03/08/2012WO2011130476A3 Polymer-based therapeutic agents
03/08/2012WO2011129936A9 Compositions and methods for the prevention and treatment of cancer
03/08/2012WO2011126324A3 Pomegranate extract having a high ellagic acid content, and use of the pomegranate extract
03/08/2012WO2011123623A3 Skin, nail and hair topical antimicrobial methods using formulations containing organosilane quaternaries
03/08/2012WO2011123619A3 Permeable mixtures, methods and compositions for the skin
03/08/2012WO2011122815A3 Novel quinoxaline derivatives
03/08/2012WO2011109200A9 The use of rhamnolipids as a drug of choice in the case of nuclear disasters in the treatment of the combination radiation injuries and illnesses in humans and animals
03/08/2012WO2011089126A3 Novel retigabine composition
03/08/2012WO2011048563A3 Orally disintegrating tablets of betahistine
03/08/2012WO2011017483A8 Sublingual and buccal film compositions
03/08/2012WO2011008548A8 Vaccines and compositions against streptococcus pneumoniae
03/08/2012WO2010124121A8 Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitor
03/08/2012WO2010094126A8 Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
03/08/2012WO2003032894A3 Method of monitoring neuroprotective treatment
03/08/2012US20120059462 Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
03/08/2012US20120059240 Method for preparation of micellar hybrid nanoparticles for therapeutic and diagnostic applications and compositions thereof
03/08/2012US20120059067 1-acetyl-5-hydroxyanthracene-9,10-dione for treatment of retinal disease
03/08/2012US20120059066 Pharmaceutical salts
03/08/2012US20120059065 Tamper Resistant Dosage Form Comprising An Anionic Polymer
03/08/2012US20120059064 Compositions and Methods For Inhibiting an Isoform of Human Manganese Superoxide Dismutase
03/08/2012US20120059063 Combinations of adapalene and benzoyl peroxide for treating acne lesions
03/08/2012US20120059062 Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions
1 ... 1321 1322 1323 1324 1325 1326 1327 1328 1329 1330 1331 1332 1333 1334 1335 1336 1337 1338 1339 1340 1341 ... 7860